Faruqi & Faruqi, LLP, a prominent national securities law firm, is investigating potential claims on behalf of investors who suffered losses related to their investments in Jasper Therapeutics, Inc. This inquiry comes in light of alleged violations of federal securities laws, particularly concerning misleading statements made by the company regarding its operational and financial standing. Investors who acquired securities in Jasper between November 30, 2023 and July 3, 2025 are urged to contact the firm to discuss their legal options.
Details of the Investigation
The investigation focuses on claims against Jasper, which trades under the ticker symbol JSPR on NASDAQ. According to the firm, the allegations suggest that Jasper and its executives failed to disclose critical information about the company’s operational controls. Specifically, the complaint alleges that Jasper lacked appropriate controls and procedures to ensure that third-party manufacturers were compliant with current Good Manufacturing Practices (cGMP). This oversight raised concerns about the reliability of ongoing clinical trial results and the commercial viability of Jasper’s products, notably briquilimab.
On July 7, 2025, Jasper released a statement detailing issues encountered in its BEACON Study, noting that certain results were affected by complications arising from a problematic drug lot. The company indicated that ten out of thirteen patients in the affected cohorts were dosed with this lot, prompting an immediate investigation. Jasper announced it would halt the study related to asthma and pause development for severe combined immunodeficiency (SCID), despite previously asserting a strong financial position.
In light of these developments, Jasper’s stock price plummeted by $3.73 per share, equating to a 55.1% drop, closing at $3.04 on the same day. This rapid decline indicates significant investor concern and highlights the importance of the ongoing investigation.
Lead Plaintiff and Class Action Options
The firm is reminding investors of the approaching deadline of November 18, 2025, to apply for the role of lead plaintiff in a federal securities class action against Jasper. The lead plaintiff is typically the investor with the most substantial financial interest in the case who can adequately represent the interests of the class.
Investors wishing to pursue their claims may do so either by designating a lead plaintiff or choosing to remain as absent class members. Importantly, participation as a lead plaintiff does not affect an individual’s ability to share in any recovery from the lawsuit.
Faruqi & Faruqi, LLP invites anyone with additional information regarding Jasper’s operations, including whistleblowers and former employees, to reach out to the firm. For further details on the class action concerning Jasper Therapeutics, interested parties can visit the firm’s website or contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
The firm emphasizes that all communications will be treated as confidential, and they welcome the opportunity to discuss individual cases. As a recognized leader in securities law since its establishment in 1995, Faruqi & Faruqi has recovered hundreds of millions of dollars for investors, maintaining a strong commitment to safeguarding their rights.
